#Biotech

Claude's Corner: Origin - The DNA Switch Startup That Beat Google DeepMind

Origin builds Axis, an AI that designs regulatory DNA sequences controlling gene expression in disease cells. It outperforms Google DeepMind's AlphaGenome by 6.7% and is building a proprietary validation dataset that could create a multi-year lead in cell and gene therapy safety.

Claude's Corner: 10x Science, When the Scientists Who Built the Field Decide to Eat the Software

A Nobel laureate lab spinout is automating the protein characterization work that pharma PhD scientists have done by hand for decades. Here is what they built, how it works, and how hard it would be to clone.

Claude's Corner: Ditto Bio -- The Startup Mining Parasites to Fix Your Immune System

Ditto Bio is using AI to mine proteins from parasites, viruses, and ticks for autoimmune drug candidates. Here's why stealing from 500 million years of evolution might actually work.

Joe Lonsdale: US Leads AI Race, But China Copies

Joe Lonsdale, co-founder of Palantir and managing partner at 8VC, discusses the US lead in AI, the Pentagon's embrace of startup innovation, and the critical need for regulatory reform.

ChemoCentryx Data Fraud Allegations Surface

Allegations of data manipulation at ChemoCentryx have resurfaced, casting doubt on FDA-approved drug trial results and raising questions about Amgen's acquisition.

Claude's Corner: Rhizome AI, The FDA Whisperer for Biotech

Rhizome AI turns 44 million FDA and EMA regulatory documents into instant, citation-backed answers for life sciences teams. Here's how they built the data moat, why it works, and how you'd replicate it.

Claude's Corner: Mantis Biotech, The Digital Twin Factory Solving Medicine's Data Problem With Physics

Mantis Biotech (YC W26) builds human digital twins by fusing LLMs with physics simulation engines to generate scientifically credible synthetic biomedical training data. Deep technical breakdown and replicability analysis.

Claude's Corner: CellType, Teaching LLMs to Speak Biology

CellType is the two-person YC W2026 company building an agentic drug discovery platform on top of a 27B biological foundation model. Their Cell2Sentence technique translates single-cell gene expression into sequences LLMs can learn from, and they've already validated a cancer immunotherapy prediction in living cells. Here's how they built it, why it's hard to replicate, and a step-by-step guide to building a clone.

Gosset AI: Drug Discovery Precision Leap

Gosset AI platform outperforms frontier LLMs in niche drug discovery by 3.2x, demonstrating the power of curated data over generic web search for R&D.

Circular Genomics Secures $15 Million Series A for Alzheimer's Blood Test

AlphaFold Protein Prediction Reshapes APAC Research

AI gene editing platform aims to make CRISPR scalable

BioCLIP 2: A Biology Foundation Model for Ecosystem Insights

Generative Antibody Design Cracks 'Undruggable' Targets

Onepot AI Secures $13 Million to Revolutionize Chemical Synthesis for Drug Discovery

The Genomic LLM is here to decode 98% of human DNA

Modulight Secures $12 Million Seed Round for Light-Based Brain Therapy

Gina Raimondo: U.S. needs to lead in AI, quantum and biotech in order to win and outcompete China

\"In order to win and outcompete China, the U.S. needs to lead in AI, quantum, and biotech.

Gina Raimondo: U.S. needs to lead in AI, quantum and biotech in order to win and outcompete China

\"In order to win and outcompete China, the U.S. needs to lead in AI, quantum, and biotech.

Primaa raises €7M to advance AI cancer diagnostics

Biotech company Primaa has raised €7 million to expand its AI cancer diagnostics software.

Primaa raises €7M to advance AI cancer diagnostics

Biotech company Primaa has raised €7 million to expand its AI cancer diagnostics software.

Lilly Blackwell Drug Discovery: A New Era

Adaptam Therapeutics Funding Targets Tough Cancer Immunotherapy Challenge

Tahoe-x1 single cell model scales AI for cancer drug discovery

Valthos AI Biodefense Secures $30M to Combat Programmable Biology

Revyve Secures €24M Series B for Egg-Replacing Yeast Proteins

Revyve, a Dutch FoodTech scale-up, has secured €24 million in Series B funding. ABN AMRO Sustainable Impact Fund and Invest-NL co-led the round.

Revyve Secures €24M Series B for Egg-Replacing Yeast Proteins

Revyve, a Dutch FoodTech scale-up, has secured €24 million in Series B funding. ABN AMRO Sustainable Impact Fund and Invest-NL co-led the round.

Biotech's AI Infusion: A Tremendous Opportunity

Synthesize Bio Raises $10M Seed for Generative Genomics

Synthesize Bio raised $10M for generative genomics. Its GEM-1 model accelerates drug discovery.

Terra Oleo Secures $3.1M for Sustainable Oil Production

Singapore-based Terra Oleo has secured $3.1 million in funding to advance its sustainable oil production technology. ADB Ventures, Better Bite Ventures, Elev8.

Terra Oleo Secures $3.1M for Sustainable Oil Production

Singapore-based Terra Oleo has secured $3.1 million in funding to advance its sustainable oil production technology. ADB Ventures, Better Bite Ventures, Elev8.

Virtual Cells: Unlocking Biology's Latent Speed with AI

Ridge Bio Secures $25M Seed for AI-Enabled Drug Design

GPT-5 Ignites Moderna's Second Computing Revolution

NRG Therapeutics Secures £50M Series B for ALS, Parkinson's Drugs

NRG Therapeutics secured £50 million in Series B funding, led by SV Health Investors’ Dementia Discovery Fund. This investment will advance mitochondrial-targeting treatments for neurodegenerative diseases. The company aims to transition its pipeline, including lead candidate NRG5051 for ALS and Parkinson's, into...

BoobyBiome Secures €2.8M Seed for Infant Health Solutions

London-based biotech firm BoobyBiome has raised €2.8 million in Seed funding. DeepTech investor Empirical Ventures led the round, supporting the company\'s a...

BoobyBiome Secures €2.8M Seed for Infant Health Solutions

London-based biotech firm BoobyBiome has raised €2.8 million in Seed funding. DeepTech investor Empirical Ventures led the round, supporting the company\'s a...

Enveda Secures $150M Series D, Achieves Unicorn Status

Treeline Biosciences Raises $200M, Initiates Clinical Trials

The company also initiated Phase 1 trials for three oncology programs, including a pan-KRAS inhibitor.

Dia Beta Labs Raises €1.4M for Diabetes Cell Therapies

Northern Ireland-based biotech startup Dia Beta Labs has secured €1.4 million in funding.

Dia Beta Labs Raises €1.4M for Diabetes Cell Therapies

Dia Beta Labs secured €1.4 million in funding from undisclosed investors. This investment will advance its development of next-generation therapies for obesity and Type 2 diabetes. The company's technology focuses on protecting and repairing insulin-producing beta-cells.

British EnsiliTech Secures €5.2M Seed for Cold-Chain Biopharma

Bristol-based EnsiliTech secured €5.2 million in Seed funding. Eos Advisory led the round, aiming to transform global biopharma transport.

British EnsiliTech Secures €5.2M Seed for Cold-Chain Biopharma

EnsiliTech secured €5.2 million in Seed funding, led by Eos Advisory. This capital will advance its patented Ensilication technology, which stabilizes biopharmaceuticals at higher temperatures. The innovation aims to eliminate cold-chain reliance, revolutionizing global biopharma transport.

German Detechgene Secures €3.2M for Mobile Lab Diagnostics

Cologne-based biotech startup Detechgene raised €3.2 million in its second Seed round. Neoteq ventures led the investment.

German Detechgene Secures €3.2M for Mobile Lab Diagnostics

German biotech Detechgene secured €3.2 million in its second Seed round, led by Neoteq ventures. The company develops 'PCR to Go', a mobile platform for fast, lab-accurate molecular diagnostics. This funding will commercialise its platform, advancing decentralized healthcare diagnostics.

AMD Ventures Backs Somite.ai with Strategic Investment to Accelerate Foundation Models for Cell Therapy

Somite.ai, a company developing foundation models for human stem cells, announced on August 20, 2025, that it has received a strategic investment from AMD V...

AMD Ventures Backs Somite.ai with Strategic Investment to Accelerate Foundation Models for Cell Therapy

Somite.ai, a company developing foundation models for human stem cells, announced on August 20, 2025, that it has received a strategic investment from AMD V...

Oxford's SugaROx Secures €1.1M for Biostimulant Scale-Up

Oxford's SugaROx secured €1.1 million in a seed round extension. The Mosaic Company led this funding round, contributing £400k. This investment accelerates the development and production of its crop-enhancing biostimulants.

Mabylon Raises €31.8M to Advance Allergy Antibody Pipeline

Mabylon, a Swiss biotech, secured €31.8 million in new funding. This investment will advance its lead peanut allergy program and early-stage pipeline. The funding came from existing private investors, including former Roche management and board members.

Mabylon Raises €31.8M to Advance Allergy Antibody Pipeline

Zurich-based Mabylon, a Swiss biotech scale-up, secured €31.8 million in new funding. This Mabylon funding round will advance its lead peanut allergy program.